EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 25 / Numéro 11 (Novembre 2009) Med Sci (Paris), 25 11 (2009) 939-944 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 11, Novembre 2009
Page(s) 939 - 944
Section M/S revues
DOI https://doi.org/10.1051/medsci/20092511939
Publié en ligne 15 novembre 2009
  1. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003; 36 (suppl 1) : S11–23. [Google Scholar]
  2. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60 : 913–20. [Google Scholar]
  3. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352 : 380–91. [Google Scholar]
  4. Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11 : 315–7. [Google Scholar]
  5. Lucet JC, Decré D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29 : 1411–8. [Google Scholar]
  6. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18 : 657–86. [Google Scholar]
  7. Nicolas-Chanoine MH, Jarlier V, et al. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect 2008; 14 (suppl 1) : 111–6. [Google Scholar]
  8. http://www.cclinparisnord.org/BMR/2007/Rapport_BMR2007.pdf. [Google Scholar]
  9. Lucet JC, Paoletti X, Lolom I, et al. Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med 2005; 31 : 1051–7. [Google Scholar]
  10. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8 : 159–66. [Google Scholar]
  11. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008; 14 (suppl 1) : 159–65. [Google Scholar]
  12. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBL in Europe. J Antimicrob Chemother 2007; 59 : 165–74. [Google Scholar]
  13. Valverde A, Coque TM, Sánchez-Moreno MP, et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42 : 4769–75. [Google Scholar]
  14. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42 : 925–34. [Google Scholar]
  15. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007; 28 : 1114–6. [Google Scholar]
  16. Goldstein FW. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 2000; 19 : 112–7. [Google Scholar]
  17. Grobost F. Épidémiologie des entérobactéries productrices deβ-lactamase à spectre élargi (EBLSE communautaires en France : enquête transréseaux dans les laboratoires de ville). Paris, France : 26e RICAI, réunion interdisciplinaire de chimiothérapie anti-infectieuse, 2006 (abstract). [Google Scholar]
  18. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23 : 163–7. [Google Scholar]
  19. Calbo E, Romaní V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57 : 780–3. [Google Scholar]
  20. Rodríguez-Baño J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42 : 37–45. [Google Scholar]
  21. Rodríguez-Baño J, Navarro MD, Romero L, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14 : 180–3. [Google Scholar]
  22. Harris AD, McGregor JC, Johnson JA, et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007; 13 : 1144–9. [Google Scholar]
  23. Lavigne JP, Marchandin H, Delmas J, et al. CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Microbiol 2007; 45 : 620–6. [Google Scholar]
  24. Valverde A, Grill F, Coque TM, et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 2008; 46 : 2796–9. [Google Scholar]
  25. Laupland KB, Church DL, Vidakovich J, et al. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008; 57 : 441–8. [Google Scholar]
  26. Reddy P, Malczynski M, Obias A, et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007; 45 : 846–52. [Google Scholar]
  27. Glupczynski Y, Huang TD, Berhin C, et al. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007; 26 : 777–83. [Google Scholar]
  28. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63 : 243–5. [Google Scholar]
  29. Thomas K, Weinbren MJ, Warner M, et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006; 57 : 367–8. [Google Scholar]
  30. Zahar JR, Lortholary O, Martin C, et al. Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs 2009; 10 : 172–80. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.